Celltrion (068270.KS) unveiled its next-generation drug development strategy and open innovation achievements, signaling its ambition to emerge as a global new drug company.
Celltrion held "Celltrion Science & Innovation Day 2026 (CSID)" at the Conrad Seoul Hotel in Yeouido, Seoul on Wednesday, the company said Thursday. CSID is an event designed to showcase Celltrion's new drug blueprint and development capabilities to the market. This year's event was held under the theme "Global New Drugs Opened Through Open Innovation."
At the event, Celltrion introduced the differentiated capabilities of its next-generation drug portfolio, including antibody-drug conjugates (ADCs), multi-specific antibodies, novel antibody and fusion proteins, peptides, and microbiome therapeutics. Celltrion CEO Seo Jin-seok took the stage as a speaker to present the blueprint for the new drug portfolio and the execution of open innovation. Kwon Ki-sung, head of Celltrion's R&D division, also explained the company's next-generation antibody development strategy, technological competitiveness, and commercialization direction. Celltrion emphasized that it is building a competitive new drug development model by combining its own accumulated development capabilities with the innovative technologies of external partners.
The scope of attendees was also expanded. While last year's event centered on the securities industry, including domestic and international analysts, this year it was broadened to include institutional investors, venture capital (VC) firms, and research institutions. The aim is to more broadly communicate Celltrion's new drug development achievements and corporate value.
Presentations from partner biotech ventures also followed at the event. Shin Min-jae, CEO of Kaizen, introduced a strategy for developing next-generation autoimmune disease treatments, while Kim Maeng-seop, CEO of Must Bio, presented the direction of immuno-oncology drug development. Lee Dae-seung, CEO of Portrai, and Seok Cha-ok, CEO of Galux, also gave presentations on spatial biology and artificial intelligence (AI)-based drug development tools, respectively.
Celltrion currently operates six open innovation programs in partnership with public institutions and universities across the country. The company plans to expand these collaboration programs to overseas markets, including the United States, Japan, and China, to broaden the new drug development ecosystem. "We will gradually communicate our new drug development achievements to the market and enhance corporate value to leap forward as a global new drug company," Seo said.
